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Abstract
A model and analysis of the human sleep/wake system is presented. The
model is derived using the known neuronal groups, and their various pro-
jections, involved with sleep and wake. Inherent in the derivation is the
existence of a slow time scale associated with homeostatic regulation, and
a faster time scale associated with the dynamics within the sleep phase. A
significant feature of the model is that it does not contain a periodic forcing
term, common in other models, reflecting the fact that sleep/wake is not de-
pendent upon a diurnal stimulus. Once derived, the model is analyzed using
a linearized stability analysis. We then use experimental data from normal
sleep-wake systems and orexin knockout systems to verify the physiological
validity of the equations.
Keywords: Sleep/Wake Cycle, circadian regulation, limit cycle, Hopf
Bifurcation
1. Introduction
Most living organisms exhibit daily biological rhythms. One of the most
curious and difficult to understand is the sleep/wake cycle. Even though we
are very familiar with sleep/wake, the reasons for sleep are not well under-
stood. What is intriguing about the sleep-wake cycle is the complex interplay
between the arousal and sleep states. Part of this is due to the cyclic alter-
ation of the rapid eye movement (REM) and non-REM (NREM) stages of
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sleep. The distribution of REM and NREM varies dramatically across the
animal kingdom, to the point that a clear pattern has not emerged. One
consequence of this is that an animal model for human sleep has not been
found [42]. Another complication is that sleep/wake is sometimes thought
to be synonymous with the 24 hour circadian clock. This is not correct.
Although sleep/wake is coupled to the circadian clock, it is regulated by a
neural system distinct from the circadian timing mechanism [34]. Sleep/wake
are also heavily influenced by two other factors. One is homeostatic, where
the need for sleep increases with the length of the wake period. The second is
allostatic, where the sleep/wake cycle is modified due to external behavioral
events [32]. The circadian process is connected to the sleep-wake cycle, while
a homeostatic process is inherent to the sleep-wake cycle. To be specific, it
is now known that the sleep-wake cycle is independent of the diurnal stim-
ulus, and is instead driven by homeostatic forces [12, 17, 1]. Therefore, the
inherent periodicity of the sleep/wake cycle is not due to a periodic forcing
mechanism associated with the diurnal cycle but is an inherent characteristic
of the system. The objective of this study is to derive, and then analyze, a
model for the sleep/wake cycle that accounts for the circadian and homeo-
static influences of sleep/wake, but not necessarily the allostatic affects. This
will include both REM and NREM sleep, as well as the waking state and
observations about the associated brainwave activity of all states.
1.1. Biological Background
A basic assumption is that the brain has two states, sleep and wake, with
sharp transitions between them. There are multiple cell groups in the brain
contributing to these states, but the monoaminergic nuclei (MN) have been
identified as primarily responsible for promoting the awake state [32]. Sleep is
primarily promoted by the ventrolateral preoptic nucleus (VLPO), which is a
group of cells associated with generating NREM and REM. A consequence of
this distinct structural organization is that although the states are coupled,
they have different regulatory mechanisms in the brain.
1.1.1. REM/NREM
The REM and NREM phases of sleep have a well defined pattern (refer
to Figure 2). Regardless of the conditions of sleep onset, a person always
begins in an NREM period of the cycle. After approximately 80-85 minutes
the brain switches to the REM stage, and remains in this state for approxi-
mately 5-10 minutes before switching back to NREM. This 90 minute pattern
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Figure 1: Approximate locations of areas pertaining to Sleep-Wake promoting neuronal
groups.
continues through the night with the REM-on intervals becoming progress-
ing longer, and the NREM-on intervals shorter. The last REM-on period
is about 25 minutes. There is no probability of waking naturally during
an NREM interval, as the NREM component occurs during the periods of
slow wave sleep. It is postulated that this is due to NREM being the most
mentally restorative of the two processes, requiring little brain function and
unconsciousness. Natural wake up occurs towards the end of the last NREM
period. [39]
There are three different ways of triggering sleep onset: exciting sleep
active neurons, inhibiting wake active neurons or a combination of the two.
The same idea applies to the triggering of wake onset. Consequently, to
investigate the source of sleep/wake brain function, it is necessary to examine
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Figure 2: The basic partitions of the states of sleep and wake for humans.
the neurotransmitter activity of the system.
1.1.2. Location Specific Neurotransmitter Activity
The chemical activity of the brain involves the secretion of hormones
and neurotransmitters from specific sections of the brain. The sleep-wake
cycle is initiated and maintained by multiple distinct neuronal regions in
the brainstem. These regions are located in the hypothalamus and are cou-
pled to each other via electrical and neurochemical signaling. Figures 3
and 4 provide a schematic of location specific neurotransmitter signal flow
in terms of excitatory and inhibitory mechanisms. Figure 1 shows the ap-
proximate locations of sleep and wake promoting areas in the human brain.
Figure 5 provides a simple depiction of the switching between wake and
sleep states and well as the switch between REM and NREM states, and
the set of neurotransmitters associated with each, as well as their excita-
tory (+) or inhibitory (-) effects. The major neurotransmitter players are
GABA (gamma-aminobutyric acid), orexin (hypocretin), histamine, acetyl-
choline, noradrenaline (norepinephrine), serotonin and dopamine. Each of
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these transmitters are located throughout the following neuronal groups:
basal forebrain (BF), raphe nuclei (RN), laterodorsal tegmentum (LDT),
pedunculopontine tegmentum (PPT), locus coeruleus (LC), lateral hypotha-
lamus (LH), tuberomammillary nucleus (TMN), ventral periaqueductal gray
region (vPAG), and ventrolateral preoptic nucleus (VLPO). Adenosine has
been proposed to be the homeostatic accumulator of the need for sleep [32].
Acetylcholine effects muscle action, learning and memory. Norepinephrine
effects one’s control of alertness and wakefulness. Dopamine effects move-
ment, focus and learning. Serotonin regulates mood, appetite, sleep, arousal
and pain threshold. GABA contributes to sleep control and appetite control.
Also note that the sections of the brain we will be focusing on are the cere-
bral cortex, hypothalamus and thalamus, which play key roles in homeostatic
maintenance. In this way they are the most relevant to the control of the
human sleep/wake system.
Figure 6 shows one full period of the sleep-wake cycle model in terms of
adenosine and GABA concentration levels. The point at which the curves
cross indicate wake or sleep initializations, depending on whether one of the
variables is increasing or decreasing. Wake Initialization occurs when GABA
is decreasing and AD is increasing. Sleep initialization occurs when AD is
decreasing and GABA is increasing.
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Figure 3: Excitatory projections of neurotransmitter flow in the sleep/wake generating
network.
Adenosine, which is a neuromodulator, plays a major role in the sleep-
wake process. It is a byproduct of adenosine-triphosphate (ATP), the main
“energy currency” of the brain, whenever neurotransmitters are fired, adeno-
sine is produced. Adenosine is also continuously converted back to ATP via
the metabolic processes that use it as an energy source [37]. The adenosine
concentration that we are most interested in is that of the basal forebrain.
While inhibiting the expression of all wake active neurotransmitters and dis-
inhibiting the expression of those found in the VLPO [7], adenosine levels in
the basal forebrain increase during prolonged wake and fall during recovery
sleep, providing an intrinsic periodic force associated with waking [30, 29].
The linear relationship between between adenosine accumulation and sleep
propensity provides support for using adenosine as representative of sleep
propensity. GABA in the VLPO can be viewed as the other major player in
the sleep-wake system. GABAA receptors in the brain mediate the tonic (or
6
BF
vPAG
LH
LDT/PPT
VLPO
LC
RN
TMN
Inhibition 
(acting on 
the area to 
which it is 
adhered
Autoinhibitory
loop
Mutual 
inhibition
Key
Figure 4: Inhibitory projections of neurotransmitter flow in the sleep/wake generating
network
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Figure 5: The cycle of NREM Sleep, REM Sleep and Wakefulness with the neurotrans-
mitters characteristic of their stages.
slow) conductance [40]. This slower type of signaling plays a key role in cell
excitability and sleep homeostasis [40]. Neuron populations in the VLPO
are inactive during the vigilance state, and have a high firing rate and level
during NREM, especially during delta wave (slow wave) sleep [40]. Being
the major inhibitory neurotransmitter in the central nervous system, GABA
is a key player in many physical systems.
Referring to the Table 1, we can see the detailed activity associated with
each neurotransmitter and brain area, allowing for the development of a sys-
tem of variables. As a simple example, OXLH is the variable associated with
the chemical concentration of orexin in the lateral hypothalamus. Since we
only discuss orexin in one location, the subscript LH can be dropped. Orexin
expression is promoted by acetylcholine in the LDT/PPT and noradrenaline
in the LC. Orexin expression is inhibited by adenosine, serotonin, GABA
and noradrenaline. Orexin promotes the release of noradrenaline, serotonin,
histamine, GABA in the basal forebrain, acetylcholine, and dopamine, as
well as promoting its own release (autoexcitation). These dynamics indicate
the need for a linear combination of acetylcholine, noradrenaline, serotonin,
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Figure 6: One full period of the sleep-wake cycle model.
dopamine, histamine, GABA, adenosine, and orexin to express the rate of
change of OX concentration.
2. Materials and Methods
In order to test the functionality of the model, we use numerical methods
to determine how the system responds to a variety of perturbations. In
the calculations to follow, MATLAB 2009a was used to run all the programs
written for the Human Sleep/Wake system described here. However, a fourth
order Runge-Kutta method was used for solving the system of equations,
instead of using one of the MATLAB ode solvers because of the unique
perturbations used in the sleep experiments described.
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Figure 7: Components of the human sleep/wake cycle as well as their associate neuro-
transmitters
3. Theory and Calculation
3.1. Previous Work
A good survey of the early sleep/wake models can be found in [35]. We
will only comment here on those most relevant to our development.
In a recent paper by Phillips and Robinson [28], a model was proposed
in order to improve quantitative understanding of the human sleep/wake cy-
cle, which is similar to the intentions of this study. They use the following
three neuronal populations to model the human ascending arousal system:
monoaminergic (MA) nuclei, acetylcholine related (ACh) nuclei, and popu-
lations in the VLPO. The VLPO is then split into circadian and homeostatic
drives, which are represented by periodic forcing functions. Each population
has its dynamics modeled by a sum of mean cell body potentials and mean
neuronal firing rates subjected to the periodic forcing of the VLPO. While
their model consistently predicts sleep/wake cycle dynamics observed in pre-
vious studies, it is important to note that the homeostatic and circadian
drives are represented as periodic forcing rather than dynamics inherent to
10
the physical system.
[10] developed a model of the network of neurons controlling behavioral
state transitions in mice, while also identifying special features of human
and mouse sleep. It is similar to the Phillips and Robinson model (as well
as the model being developed here) in that it defines three main processes
being modeled: Sleep activity, Wake activity, and REM activity. Each pop-
ulation is defined by a set of three equations, determined by a wide range in
timescales. It incorporates homeostatic REM and NREM sleep drive and uses
known sleep active neurotransmitters to determine parameters. It then uti-
lizes extensive experimental data gathered from mouse sleep/wake states to
verify the accuracy of the model. A limitation of their approach concerns the
separation of vigilance states, which are characterized in a non-quantitative
fashion. Similarly, “activity states” are used rather than specific neurotrans-
mitter concentration and/or neuron firing data.
Taking a somewhat different viewpoint, [31] use the “flip-flop” dynamics
proposed in [32] to construct a biologically-based mathematical model that
accounts for several features of the human sleep/wake cycle. This differs
from our model in several ways, but two examples are that they assume,
incorrectly, that the SCN projects directly to the VLPO, and an external
periodic forcing mechanism is used to drive the model.
In another recent paper by [9], a model of the rat sleep/wake regula-
tory network is formed utilizing similar techniques as those used to model
a mouse sleep/wake regulatory network in her aforementioned work [10]. In
this model, neurotransmitter concentrations are coupled to neuronal group
firing rates to create a more complete view of the hypothalamic sleep-wake
regulatory network. The model is composed of three parts: wake/sleep active
neuron population firing rates, wake/sleep active neurotransmitter concentra-
tions and a homeostatic regulator. All physical parameters were determined
using extensive experimental data. This paper emphasizes the importance of
utilizing neuron firing rates as well as neurochemical concentrations to form a
physiologically accurate model of sleep/wake regulation. A downside of this
model lies in the use of steady state saturation functions and Heaviside func-
tions. Rather than using inherent neurotransmitter dynamics, the functions
of neurotransmitter release are approximated using sigmoidal functions. The
homeostatic drive is a physically unquantifiable force composed of Heaviside
11
switching mechanisms.
3.2. Model Formulation
In this model for the sleep/wake cycle, we are considering three principal
states. They are the wake state (W ), the NREM sleep state (S) and the
REM sleep state (R). Table 1 provides a framework for the detailed interac-
tions of all the neurotransmitters involved in the sleep-wake system. Given
the number of variables involved, before deriving the equations it is worth
describing the dynamics in more qualitative terms.
The sleep-specific and wake specific neurotransmitters operate on a slow
time scale, measured in terms of hours, while the REM and NREM specific
neurotransmitters operate on a fast time scale system, measured in terms of
minutes. The two neurochemicals associated with the slow time scale are
adenosine in the BF and GABA in the VLPO. We use these two concentra-
tions as variables indicating promotion of wake and sleep. High adenosine
concentrations in the BF promote wakefulness, while high GABA concentra-
tions and fast firing rates in the VLPO promote sleep. Adenosine’s slow build
up and decay is associated with wakefulness, while GABA in the VLPO is as-
sociated with sleep. These observations are the basis for the hypothesis that
adenosine is the principal component in determining wake, and GABAV LPO
is the principal component in promoting sleep [40, 30, 29]. We also know
from these references that AD disinhibits the VLPO during slow wave sleep,
providing a direct connection between the building adenosine sleep pressure
during waking and the gradual relief of this pressure during sleep. The other
neurotransmitters are assumed to be associated with the fast time scale dy-
namics. Adenosine and GABAV LPO fluctuate with a period of 24 hours,
while the other neurotransmitters fluctuate with a period of several minutes.
An important inherent quality of the sleep-wake cycle is that it should
maintain it’s state transitions in the absence of external periodic forcing.
Mathematically, this indicates the need for the system to have a stable (at-
tracting) limit cycle. This solution should also be stable to certain perturba-
tions, such as those that might occur from genetic mutations causing the pro-
duction of too much or too little of a neurotransmitter, or lacking the proper
neuron groups to produce a neurotransmitter at all. Perturbations may also
occur via the removal of specific neuron groups, blockage of neurotransmitter
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bonding sites, and external forcing. It is well known from experimental data
that perturbations to neurotransmitters don’t alter the two-state nature of
the sleep-wake system [30, 29, 3, 27, 16, 22, 21, 20, 5, 11, 23, 8, 14, 4]. As
an example, cholinergic agonists applied to the LC in cats leads to increased
REM sleep, but the sleep-wake cycle as a whole remains periodic [8]. There-
fore one of the central goals will be to locate the area in the phase plane of
GABAV LPO and AD where a limit cycle exists and is stable.
3.2.1. Kinetics
For each neurotransmitter involved in the sleep-wake system, we iden-
tify a location specific variable representing the effective neurotransmitter
concentration. We assume first order kinetics for the neurotransmitters op-
erating on the fast time scale. The fast time system may be formed from the
observations compiled about the inhibitory and excitatory nature of the neu-
rotransmitters in Table 1 combined with the dynamics arising in a synapse.
If Xi is representative of a neurotransmitter in region i, we have
dXi
dt
= Release(t)− Uptake(t)−Degradation(t). (3.1)
Note that inhibitory effects are considered pre-synaptic and are therefore
controlling flow from the neuron into the synaptic gap. Despite the fact that
inhibitory and excitatory effects can occur pre- or post-synaptically, for sim-
plicity we will assume the blocking or binding process of inhibition as only
controlling flow into the gap. The Release function contains rate parame-
ters and neurotransmitter variables that excite and inhibit the expression
of Xi. The Uptake function depends on Xi and its associated vesicular up-
take transporter, if existent. The Degradation function depends on Xi and
an associated rate of decay. The uptake transporters are modeled using
known logistic dynamics from neurotransmitter uptake transporter micro-
dialysis measurements [26].
As an example, the release of histamine is promoted by orexin, nora-
drenaline and acetylcholine in the BF and inhibited by GABA in the VLPO.
Histamine is autoinhibitory, like most of the monoamines. The equation for
histamine’s rate of change, like all of the other neurochemicals involved, also
requires an adenosine term. Histamine in the human sleep-wake system has
no known uptake mechanism, and so only degrades as a method of removal.
13
Therefore the equation for histamine is
dH
dt
= ciOX+ci+1NA+ci+2AChBF+ci+3AD−ci+4GABAV LPO−(ci+5−ci+6)H
where the ci’s are rate coefficients. The rest of the equations are formulated
in the same fashion.
Fast Time System
dGABABFw
dt
= c1AChBF + c2OX + c3AD − c4GABABFw−
c5(GA1)(GABABFw) (3.2)
dGABABFs
dt
= c6AD + c7NA− c8GABABFs − c9(GA1)(GABABFs)
(3.3)
dOX
dt
= c10AChLDT/PPT + (c11 − c12)NA+ (c13 − c14)OX + c15AD−
c16S − c17GABAV LPO + c18GABABFs (3.4)
dH
dt
= c19OX + c20NA+ c21AChBF + c22AD − c23GABAV LPO−
(c24 − c25)H (3.5)
dAChBF
dt
= c26OX + c27H + c28AD − c29S + c30GABABFs − c31AChBF
(3.6)
dAChLDT/PPT
dt
= c32OX + c33H + c34AD + c35NA− c36S − c37AChLDT/PPT
(3.7)
dNA
dt
= c38OX + c39AChBF + c40AD − c41GABAV LPO−
(c42 − c43)NA− c44(hNET )(NA) (3.8)
dS
dt
= c45OX + c46H + c47NA+ c48AD − c49GABAV LPO−
(c50 − c51)S − c52(hSERT )(S) (3.9)
dDA
dt
= c53OX + c54S + c55AChLDT/PPT + c56NA+ c57AD−
c58GABAV LPO − c59(hDAT )(DA)− c60DA (3.10)
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The uptake transporter values are contained in the uptake terms in equa-
tions (3.2), (3.3), (3.8), (3.9) and (3.10). Their values are found from mi-
crodialysis experiments with human cerebrospinal fluid (CSF), and are as
follows [26]: GA1 = 1, hNET = 0.457, hSERT = 0.463, hDAT = 1.22.
3.2.2. Uptake Mechanisms
The neurotransmitters involved in the sleep-wake system, as with any
neuronal network, have natural rates of removal from the synaptic gap once
released. These rates can either be contributed to by degradation, neuro-
transmitter uptake or a combination of both. All of the neurotransmitters
involved degrade over time, but only some have neurotransmitter uptake
mechanisms. We will not be considering any of the smaller scale chemi-
cal dynamics of the neurotransmitter uptake mechanisms. We care only
whether a neurotransmitter is removed by an uptake mechanism, and will
not differentiate between plasma membrane-bound transportation or recep-
tor uptake. The key take away from the uptake transportation data is that
only GABA, noradrenaline, serotonin and dopamine have significant synap-
tic uptake transport mechanisms in humans. These mechanisms are char-
acterized by the data given constants GA1, hNET , hSERT and hDAT
for GABA, noradrenaline, serotonin and dopamine, respectively [26]. These
neurotransmitter transporters appear in the uptake term of the equations,
always multiplied by the neurotransmitter it is dependent on to indicate a
linear removal rate. As an example, hSERT appears in equation 9 multi-
plied by −c52S, so as to act as a removal mechanism for serotonin when it is
present. However, hSERT does not multiply the natural degradation term
−c50S.
3.2.3. Nonlinear Dynamics
There are two neurotransmitters, AD and GABAV LPO, operating on a
slow time scale that define the sleep-wake cycle. The qualitative portrait
in phase space is known from basic sleep-wake cycle activity. We can con-
struct the desired closed orbit and concentric curves from the nullclines of
the AD and GABAV LPO equations. We identify the bounding region in
the phase space activity by the box contained between (AD,GABAV LPO) =
(ADmax, GABAmin) and (ADmin, GABAmax). We choose small values of
ADmin = GABAmin = 0.001 rather than exactly zero to prevent inclusion of
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a potentially unstable steady state. We can scale the size of this box accord-
ing to the values of ADmax and GABAmin. These two points are represented
by the intersections of the AD and GABAV LPO nullclines. To describe the
activity between these two points, we begin with the fact that when AD is at
it’s maximum value, GABAV LPO is at it’s minimum value (0.001). This sig-
nifies that at the peak of wake activity, sleep activity is at its minimum. As
we move along the AD nullcline, the concentration of AD decreases to 0.001
as the concentration of GABAV LPO increases to GABAmax. From the point
(GABAV LPO, AD) = (GABAmax, 0.001), we move along the GABAV LPO
nullcline slowly until we reach the point (GABAV LPO, AD) = (0.001, ADmax)
again, creating a closed orbit. Figure 8 shows this movement in the phase
plane, as well as showing the location of the fixed point and neighboring
trajectories. Everything is in non-dimensional form, and therefore should be
thought of in terms of threshold levels rather than micro-moles per liter.
The system is made up of two widely separated time scales: the slow, 24
hour time scale that is governed by the build-up and decay of adenosine, and
the fast, O(1) (minute) time scale that involves interactions of all the sleep
and wake active neutrotransmitters, but is regulated by the oscillation of the
slow time scale.
We begin by forming the slow time system that will later be shown to
be responsible for the limit cycle dynamics of the system. This system is
comprised of two equations: the adenosine equation that fluctuates with
wake activity, and the GABA in the VLPO equation that fluctuates with
NREM sleep activity. We consider NREM sleep to be the ground state of
the sleep-wake system, and all other oscillations to be deviations thereof. The
adenosine equation must involve a constant source term, due to adenosine’s
constant creation as a by-product of neuronal activity, as well as a decay
term that is dependent on adenosine’s natural rate of degradation as well as
it’s loss from the synaptic gap through the its disinhibition of GABA in the
VLPO [7]. It is well known that mechanism for receptor binding is nonlinear
[26], and so the disinhibition effect of GABAV LPO via adenosine should be
nonlinear. It also follows that this nonlinear term should appear in both the
equations for AD and GABAV LPO because adenosine’s disinhibition of the
VLPO both depletes the concentration of adenosine while simultaneously
(and with the same rate) adding to the GABAV LPO concentration. The
GABAV LPO equation must contain the uptake term for GABA, a degrada-
16
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Figure 8: The ideal activity of the two neurotransmitter nullclines in the GABAV LPO−AD
phase plane.
tion term and a contribution from adenosine as well as the inhibitory and
excitatory of other neurotransmitters. A constant loss term is required in the
GABAV LPO equation as a representation of its quick breakdown time in the
synaptic gap [40]. Though it is being broken down quickly and continuously,
GABAV LPO still provides a tonic effect on the sleep-wake system as a whole
[40]. Based on these requirements as well as the observations of the glycolysis
reaction [33], we obtain the following slow time system:
Slow Time System
dAD
dt
= k1 − k2AD − (GABAV LPO)2(AD) (3.11)
dGABAV LPO
dt
= −− k3GABAV LPO + k4AD+ (GABAV LPO)2(AD) (3.12)
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where
 = µ− (a1AChBF + a2AChLDT/PPT + a3NA+ a4S + a5DA)
To provide a more physical explanation of the assumed reaction system, we
know that adenosine is a bi-product of the constant source of energy in the
nervous system, adenosine triphosphate (ATP). We know that adenosine is
continuously converted back into ATP [37]. From experiments in the VLPO,
we know that activation of VLPO neurons through adenosine-mediated inhi-
bition contributes to the somnegenic actions of adenosine, and only adenosine
acts directly on the VLPO in the sleep-wake system [7, 3, 30, 29]. During
wake, increased levels of adenosine promote sleep by disinhibiting the release
of GABA in VLPO. Adenosine levels in this area increase during wake and
decrease during sleep [7]. In this way the physical foundation for the glycol-
ysis system is similar to and provides a good framework for our slow time
scale system.
3.2.4. Characterizing REM/NREM
REM and NREM sleep are determined by a nonlinear combination of
neurotransmitters. Specifically, GABAV LPO promotes the state of REM
sleep, as does acetylcholine from both the LDT/PPT and the BF. While
NREM can be seen as an absence of the vigilance state and the contributions
from GABA, REM sleep must incorporate contributions from neurotransmit-
ters active in the wake state as well as those in the NREM state. Letting
R(t) represent the REM sleep state, we assume that R′′ + ΦR′ + ΓR = 0.
To determine Φ, note that the transition from the waking state to the
sleeping state, and vice versa, occurs when GABAV LPO = AD. Given
that the REM state has an asymptotically stable steady state during wake,
which occurs when AD > GABAV LPO, and has a limit cycle during sleep,
which occurs when AD < GABAV LPO, then Φ contains a term of the form
(GABAV LPO − AD)(R2 − R20). When entering wake, so GABAV LPO = AD
and ˙AD > 0, there is an impetus for the impending dormancy of REM and
the resulting mathematical requirement is that Φ( ˙AD,AD) > 0. Likewise,
when entering sleep, so GABAV LPO = AD and ˙AD < 0, the requirement for
the oncoming REM limit cycle is Φ( ˙AD,AD) < 0. This gives us
d2R
dt2
+
[
α(GABAV LPO − AD)(R2 −R20) + β
dAD
dt
]
dR
dt
+ ΓR = 0 . (3.13)
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3.2.5. Some Special Cases
Given the complexity of (3.13), it is worth considering the solution in
particular situations and then using this to help estimate the oscillatory
response of equation (3.13). For example, the period for R can be determined
from the fact that there are three to four normal REM oscillations over a
normal night’s sleep. So, when GABAV LPO = AD,
d2R
dt2
+ β
dAD
dt
dR
dt
+ ΓR = 0 . (3.14)
Given the slowly varying nature of AD, then R = ert, where r = 1
2
(−βu ±√
β2u2 − 4Γ) and u = (AD)′. Since u strongly controls the decay, and to
have Γ control the number of REM oscillations, we require r = −u ± i√γ,
where
√
γ is approximately the number of oscillations. Thus, β = 2 and
Γ = γ + u2. From this we have that
d2R
dt2
+2
[
(GABAV LPO − AD)(R2 − 1.3) + αdAD
dt
]
dR
dt
+
(
γ +
(
dAD
dt
)2)
R = 0 .
(3.15)
where α is determined numerically and 8 < γ < 16.
Based on Lienard’s Theorem, we know that the above oscillator has a
unique, stable limit cycle [36]. Thus the REM oscillations will continue to
function in a stable, periodic fashion even when subjected to reasonable per-
turbations. Evidence of this result is in the Orexin Knockout section.
3.3. Analysis
To find the values of the coefficients of the system and to ensure stabil-
ity, we present several methods of analyzing the equations. We begin with
the limit cycle coming from the Slow Time System. As stated earlier, the
adenosine equation drives the wake state dynamics, and the GABA equation
drives the sleep state dynamics. The specific equations are
d
dt
AD = k1 − k2AD − (GABAV LPO)2(AD) (3.16)
d
dt
GABAV LPO = −−k3GABAV LPO+k4AD+(GABAV LPO)2(AD), (3.17)
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where
 = µ− (a1AChBF + a2AChLDT/PPT + a3NA+ a4S + a5DA).
It is not possible to determine the rate constants with the available ex-
perimental evidence. So, we take a different tack and establish bounds on
the constants that will produce the responses known to occur in sleep and
wake. To begin, we compute the nullclines of the slow time system in order to
create a trapping region for the limit cycle and to determine the coefficients
of the system by using an approximate fixed point. We have four coefficients
to determine (k1, k2, k3, k4) as well as reasonable values for the parameter
. Plugging the approximate fixed point into both nullclines will give us two
equations with five unknowns. In order to make the system well determined,
we observe the maxima and minima of the equations as well as the linearized
slow time system with the approximate fixed point. Knowing the form of
the determinant and the trace of this system needed to maintain stability,
we can determine the rest of the unknowns.
Now, solving the nullcline equations obtained from 3.16 and (3.17) for
AD and we have
AD =
k1
k2 +GABA2V LPO
,
and
AD =
k3GABAV LPO − 
k4 + (GABAV LPO)2
.
Setting these equal to each other, we have three points of intersection, only
one of which is real. Using GABAV LPO ∈ [0, 2] and AD ∈ [0, 2] as the
boundaries of the trapping region, we can approximate a fixed point inside
the closed orbit at GABAV LPO = 0.703 and AD = 0.823. This provides us
with two of the needed equations.
We also know that each of these equations is zero separately when AD =
ADmax and GABAV LPO = GABAmin, as well as when AD = ADmin and
GABAV LPO = GABAmax. We let ADmax = GABAmax = 2 and ADmin =
GABAmin = 0.01. Taking  = 0.3, and using the stated values for the
max and min concentrations it follows that k1 = 0.49, k2 = 0.1, k3 = 0.3.
k4 = 0.15. We also note that 0.29 <  ≤ 0.32 for the system to remain stable.
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3.3.1. Remaining Coefficient Estimation
Now that the coefficients for the slow time system are determined, we can
use the requirements that the eigenvalues have either pure imaginary form
or negative real parts in the complex form to determine the coefficients of
the entire system. We have the solution vector of the linearized system as x =
[GABABFw, GABABFs, OX,H,AChBF , AChLDT/PPT , NA, S,DA,AD,GABAV LPO]
T .
The matrix of coefficients and linearized values for the system are given in
Table 2.
In order for the system to be stable, we require that the real parts of the
eigenvalues to be negative. Restricting the coefficients to all be between 0
and 1, we use an algorithm that generates coefficients that keep the real parts
of the eigenvalues negative. We also note that the coefficients in GABAV LPO
equation need to be small compared to the rest of the coefficients in order to
keep  bounded.
3.3.2. Sub-Systems
When analyzing such a large system of equations with undetermined co-
efficients, it is helpful to break the large system into smaller sub-systems and
observe the dynamics on a local scale. We can utilize the neurophysiology
of the physical neurotransmitter sub-systems to determine the coefficients as
well as the stability profiles of the individual sub-systems. We break the sys-
tem up into to following categories: NREM Specific, Sleep Specific (NREM
Inclusive), Wake Specific, REM + NREM Specific, REM + Wake Specific,
Wake Inclusive, Sleep Inclusive, REM Inclusive. Note that there is no set
of equations associated with REM only. The categories represent what neu-
ron populations are active during the corresponding states. We observe the
steady-state behavior of each sub-system. Since we know the relative mag-
nitude of the neurotransmitter amounts as well as their dynamic behavior
during the states of REM, NREM and Wake, the coefficients of these smaller,
more manageable systems should be more easily attainable. This also allows
us to observe the more manageable systems for potentially extreme behavior,
and provides us with bounds to prevent this from happening. This analy-
sis does not give us specific values for the system coefficients, knowing the
relative values makes visualizing the system easier as well as simplifying the
eigenvalue analysis.
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NREM Specific
The NREM specific system involves the neuron population only active
during the state of NREM sleep. The neuron population that is only active
in NREM sleep is the GABAergic population in the BF. We assume all
equations but dGABABFs
dt
to be equal to zero, making each neurotransmitter
other than GABABFs constant, and assume the other neurotransmitters in
the equation to be at their steady state values when only GABABFs is active.
This is not necessarily a physiologically accurate view of the system for an
extended length of time, but we can view a snapshot of this activity. We
follow this same criteria for the rest of the small systems.
Wake Specific
The Wake specific system involves neuron populations with the most
activity during the wake state. The monoaminergic neuron populations (in-
cluding OX, H, NA, S and DA) are most active in this state.
Sleep Specific (NREM Inclusive)
The Sleep Specific system involves neurotransmitters that promote sleep
states (REMS and NREMS). The populations that are active in this state
are GABAergic populations in the VLPO and BF.
REM + Wake Specific
The REM and Wake Specific system involves neurotransmitters that pro-
mote REMS and the Wake state. The neuron populations that are active
during these states are GABAergic populations in the BF and cholinergic
populations in the BF and LDT/PPT.
REM + NREM Specific
The REM and NREM Specific system involves neurotransmitters promot-
ing REM sleep and the NREM sleep. The neuron population that is active
during these states is the GABAergic population in the VLPO.
Wake Inclusive
The Wake Inclusive system involves neurotransmitters that promote the
Wake state as well as those that promote both Wake and REMS. The neuron
populations that are active during these states are the GABAergic population
in the BF, the cholinergic population in the BF and LDT/PPT, and the
monoaminergic populations.
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Sleep Inclusive
The Sleep inclusive system involves neurotransmitters associated with
NREM specific, REM and NREM specific, and Wake and REM specific
states. The neuron populations that are active during these states are
GABAergic populations in the VLPO and BF, and cholinergic populations
in the BF and LDT/PPT.
REM Inclusive
The REM Inclusive system involves neurotransmitters associated with the
Wake and REM specific and REM and NREM specific states. The neuron
populations that are active during these states are the GABAergic popula-
tion in the VLPO, the wake promoting GABAergic population in the BF as
well as the cholinergic populations in the BF and LDT/PPT.
This analysis allows for an approximation of the coefficients, but it does
not yield exact values for these coefficients. Figures 11 and 12 show the
change in concentration levels of Acetylcholine in the BF and GABA in the
BF, respectively over a period of 24 hours. The remainder of the neurotrans-
mitters involved show the same fluctuations as that of Acetylcholine, whereas
GABA in the sleep active portion of the BF is unique.
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Figure 9: Concentration levels of
Acetylcholine in the BF over 35
hours.
4. Results and Discussion
The results of the implemented normal, unperturbed, system are shown
in Figures 11-14. Figure 11 depicts the slow time variables (which are the
easiest to visualize on a large time scale) AD and GABAV LPO. The AD
curve represents the non-dimensional amount of adenosine accumulation in
the BF, which consequently measures sleep pressure. The GABA curve rep-
resents the non-dimensional amount of GABA accumulation in the VLPO,
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which is a measure of wake pressure. Both exhibit a rapid transition be-
tween sleep and wake states as well as ongoing periodic behavior for nine
days. The system runs like this for much larger periods, demostrating that
unless perturbed, the sleep-wake cycle is a self-sustained, periodic oscillation.
The period of each cycle is approximately 24 hours - the wake state occupies
roughly two-thirds of this time, while the sleep state makes up the remain-
ing one-third. This is consistent with our knowledge of the structure of the
human sleep-wake cycle. Figure 12 depicts one cycle in the GABA − AD
phase plane, showing the exact behavior we required from our previous null-
cline analysis. Figure 13 is the isolated REM curve for 30 hours. Figure
14 shows the AD, GABA and REM curves simultaneously in a sample 48
hour time slice. The REM/NREM oscillations respond quickly to the tran-
sitions between wake and sleep, and cycle through three to four oscillations
in the designated eight hour sleep period. From the biological background
and neurotransmitter details, this displays physiologically reasonable results.
4.1. Orexin Knockout Experiment
Narcolepsy is a neurodegenerative disease where there is a loss of neu-
rons containing orexin (OX) [13]. It has been shown to exist across many
mammals, and has been studied extensively in mice. Here, we take infor-
mation from the sleep-wake cycles of orexin knock-out (which means the
targeted destruction of orexin neurons) mice. These mice exhibit the nar-
colepsy symptoms of sleep fragmentation, sleep onset during REM sleep
states and increased spontaneous REM and NREM sleep during the vigi-
lance state [27, 41, 4, 25, 15].
A reasonable method to represent the orexin knock-out perturbation to
the system is to change the flux of the OX amount equation. Rather than
24
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Figure 11: Adenosine and GABA (in the VLPO) levels of the sleep-wake cycle model over
216 hours (9 days).
take orexin out all together, we limit the rate at which orexin is produced,
but keep the removal factors the same. This is a reasonable way to represent
the physiological destruction of orexin neurons, since none of the uptake and
removal mechanisms are necessarily effected. It has been shown that levels of
orexin decrease in human cerebral spinal fluid by at least 80 percent [13], and
so we multiply orexin producing elements of the OX equation (AChLDT/PPT ,
NA, OX and AD) by 0.2. Implementing these changes numerically, the
periodicity and limit cycle of the system is maintained with orexin decrease.
This is illustrated in Figure 15, which clearly shows the same characteristics
as seen in Figure 11. However, we also don’t see the stereotypical changes
to the transition rates between behavioral states characteristic to narcolepsy.
We have shown that the system can withstand perturbations [27], but may
need to think of implementing another method of making genetically specific
perturbations. This also shows that orexin may have to play a larger role
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Figure 12: Phase plane of sleep-wake cycle model for one cycle.
in measuring behavioral state instability, and may have to withstand more
non-linear changes to its equation when investigated further.
4.2. Sleep Camp Data
[6] describes experiments related to perturbations in an individuals sleep/wake
cycle. The trials performed were carried out in a controlled situation with
a group of 40 adolescents over a period of one week. The perturbations
performed were delayed sleep and wake onset, prolonged sleep and wake pe-
riods and forced wake. These perturbations were achieved without the use of
external chemical stimuli, and so were essentially achieved in a noninvasive
fashion. Salivary cortisol and melatonin levels were recorded daily as well
as frequent EEG readings for accurate brainwave activity. The initial time
and length of the perturbation period were recorded, and so this data was
easy to translate into perturbations in the model. About 50 perturbations
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were introduced (which translates to a period of about 10 days) and their
effect on the system was recorded using graphical and data analysis methods.
The perturbations to the system were only introduced to one variable
- adenosine. Forced sleep and wake were achieved by forcing AD to its
maximum at the appropriate forced waking initialization, and forcing AD to
its minimum at the appropriate forced sleep time. These sleep and wake times
as well as the prolonged sleep and wake periods were taken from a data set of
seven adolescent individuals. Once perturbed the amount of times done so in
the physical experiment, we allow the system to run without perturbation for
several cycles. This entire set of perturbations and the response is depicted in
Figure 16. Figure 17 shows what the subject’s cycle would look like without
perturbation. One can see that the perturbations cause small scale (on the
order of a day or two) changes in the length of sleep or wake state. However,
27
100 105 110 115 120 125 130 135 140 145 150−6
−4
−2
0
2
4
6
Time t (hours)
Th
re
sh
old
 L
ev
els
REM−NREM Visualization
 
 
A = Adenosine
G = GABA
R = REM Activity
Figure 14: Unperturbed system of AD, GABA and REM from hours 150 to 200 - over two
days.
once allowed to run unperturbed, the system settles back into a regular 24
hour period. Initial wake and sleep times have drifted, but that is to be
expected. When run for a longer time, the system will eventually drift back
into its original phase with the same wake and sleep initialization times as the
subject started with. We know this is an accurate response to these non-drug
related, small perturbations(REF). Figures 18 and 19 show a quantitative
measure of the changes in period in the unperturbed vs. the perturbed
cycles. Figure 20 demonstrates the upholding of limit cycle dynamics in the
face of perturbations, and also that the AD−GABA phase plane retains its
size and shape but drifts in phase.
5. Conclusions
We have presented a model of the human sleep-wake generating system
that identifies specific neuronal regions in the brain with their associated neu-
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Figure 15: Orexin knockout system over 216 hours (9 days).
rotransmitters and projections. It accounts for the homeostatic influences of
sleep-wake, and has the potential to encompass circadian influences as well.
It improves upon previous models of sleep-wake cycles in that the oscilla-
tions are self-sustaining without the use of external periodic forcing, and it
is formulated specially to look at the specific sleep-wake cycle of humans.
We use the known neurochemical dynamics of the human sleep-wake cycle to
derive equations and form the stability criteria for mathematical phenomena.
Since based on limit cycle dynamics, the system runs with the contributions
of all the necessary neurotransmitters and with no need of an external driv-
ing force. This system gives reasonable predictions for “natural” sleep bout
duration, wake bout duration, REM bout duration and NREM bout dura-
tion, as well as estimated natural sleep initiation and wake initiation times.
The NREM sleep state is considered the ground state from which all other
activity deviates, and REM activity is determined from the difference of the
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Figure 16: Perturbed slow time system with forced wake onset and forced sleep onset over
a one week period. Extended time to show phase drift and maintained periodicity.
wake and NREM states, as well as the contributions from REM active neuro-
transmitters. Using experimental data from a mammalian orexin knockout
system as well as simply and non-chemically perturbed human sleep-wake
cycles, we were able to visualize the perturbed cycle and compare to the
experimental results without instability occurring. We can draw a number
of conclusions from the resulting model. In the human systems, given forced
prolonged waking, sleep duration reacts accordingly to build up appropriate
wake pressure. Once the cycle is restored to normal sleep onset and wake on-
set, the same period for an unperturbed system is maintained. The system
exhibits some phase drift with this forcing. Given forced prolonged sleep,
wake duration also reacts accordingly to build up appropriate sleep pressure.
Once the cycle is restored to normal sleep and wake onset, the periodicity is
maintained. The system exhibits some phase drift with this forcing. Given
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Figure 17: Unperturbed cycle allowed to run for the same amount of time as the perturbed
cycle.
forced wake up during sleep, the subject does not stay awake for long, and
falls back into a normal sleep schedule, yielding only some phase drift that
is corrected after a few cycles. A subject’s REM/NREM cycle goes through
three or four oscillations per state (REM or NREM). The first NREM sleep
stage is triggered by sleep onset, or when adenosine levels fall below a cer-
tain threshold and GABA becomes the dominant neurotransmitter. The last
REM cycle is turned off by wake onset, or when adenosine pressure builds
back up and GABA decays. Subjects naturally fall asleep and wake up at the
intersection points of the GABA and Adenosine thresholds - falling asleep
when enough sleep pressure from AD has been accumulated, and waking up
when the sleep pressure has decayed once again and when the subject has
gone though three to four cycles each of REM and NREM sleep. We can see
that given no external forcing (no stimuli, drugs, etc), a “normal” human’s
sleep-wake schedule unfolds in a periodic, 24 hour fashion that endures in-
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Figure 18: Examination of the length one period in an unperturbed cycle.
definitely unless given some sort of perturbation.
It is important to note the implications of the differences between home-
ostatic and circadian drive, and the importance of both of these drives’ effect
on sleep. Unlike most recent neurochemically driven models, ours has no
need for external forcing to keep it periodically driven. The periodic, limit
cycle activity arises naturally from the neurotransmitter dynamics and the
equations themselves. This demonstrates an intrinsic, homeostatic force that
keeps the human sleep-wake cycle functioning without a change in periodicity,
regardless of whether circadian control is included or not. The perturbations
in the experimental section demonstrate that even when subjected to strong
forcing, the sleep-wake cycle retains its natural 24 hour period, and shifts in
phase are the only real artifacts of outside forcing. The next step would be
to develop a more complete predictive model of the human sleep wake cycle
for use in the scientific and medical fields.
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Parameter Value Parameter Value
GA1 1 c27 0.10973
hNET 0.457 c28 0.32943
hSERT 0.463 c29 0.57879
hDAT 1.22 c30 1
k1 0.49 c31 0.02091
k2 0.1 c32 0.12648
k3 0.3 c33 0.23472
k4 0.15 c34 0.57122
µ 0.3 c35 0.02332
α 1 c36 1
γ 8 c37 0.61305
c1 0.75709 c38 0.06864
c2 0.28014 c39 0.08638
c3 0.61048 c40 0.1
c4 0.76636 c41 0.543
c5 0.32431 c42 0
c6 0.83153 c43 0.13822
c7 0.03471 c44 0.35956
c8 0.01 c45 0.11839
c9 0.19577 c46 0.13753
c10 0.79157 c47 0.1
c11 0.97026 c48 0.537
c12 -1 c49 0
c13 0 c50 0.67749
c14 0.36341 c51 0.53609
c15 0.70633 c52 0.36464
c16 0.1 c53 0.59591
c17 0.97643 c54 0.75091
c18 0.56740 c55 0.1
c19 0.91859 c56 0.22
c20 0.50364 c57 10
−5
c21 0.23758 c58 10
−5
c22 0.1 c59 10
−5
c23 1 c60 10
−5
c24 0 c61 10
−5
c25 0.92037
c26 0.04185
Table 3: Coefficient and parameter values used in the sleep-wake cycle model.
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Figure 20: Perturbed GABA-Adenosine phase plane.
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